PDE4 inhibitors: Sustained patenting activity as leading drugs near the market

Expert Opinion on Therapeutic Patents

Volumn 10, Issue 9, 2000, Pages 1415-1427

  Norman, P ^a  

^a NONE   (United Kingdom)

Author keywords

Asthma; COPD; Dermatitis; Leukaemia; PDE4 inhibitor; Pruritus; Rheumatoid arthritis; TNF

Indexed keywords

1,8 NAPHTHYRIDINE DERIVATIVE; 3 (3 CYCLOPENTYLOXY 4 METHOXYBENZYL) 6 ETHYLAMINO 8 ISOPROPYL 3H PURINE; BAY 19 8004; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BENZOFURAN DERIVATIVE; BRL 61063; CATECHOL DERIVATIVE; CDC 801; CILOMILAST; CIPAMFYLLINE; D 4418; FURAN DERIVATIVE; HEP 688; LACTONE DERIVATIVE; MORPHOLINE DERIVATIVE; N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; NICOTINAMIDE DERIVATIVE; PD 189659; PHOSPHODIESTERASE IV INHIBITOR; PHTHALAZINE DERIVATIVE; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROFLUMILAST; ROLIPRAM DERIVATIVE; TOLAFENTRINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; LEUKEMIA; PATENT; PRURITUS; PSORIASIS; REVIEW;

EID: 0033863331     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.10.9.1415     Document Type: Review

References (35)

1. PDE4 inhibitors 1999
2. The therapeutic potential of PDE4 inhibitors
3. COPD, new developments and therapeutic opportunities
4. New study shows ariflo, SmithKline Beecham's investigational PDE4 inhibitor, improved pulmonary function in chronic obstructive pulmonary disease
5. Potential of phosphodiesterase Type IV inhibitors in the treatment of rheumatoid arthritis
6. Phosphodiesterase isozymes. Molecular targets for novel anti-asthma agents
7. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here?
8. Inflazyme announces selection of phosphodiesterase-4 inhibitor without potential for emesis - Data to be presented at chase H and Q healthcare conference
9. Safety of ariflo in a 12-month study of patients with asthma
10. Ariflo efficacy in a 12-month study of patients with asthma
11. Ariflo, a novel and selective oral PDE4 inhibitor, has a favorable metabolic profile with low potential for drug-drug interactions
12. Ariflo, a novel and selective oral PDE4 inhibitor, has linear pharmacokinetics and high bioavailability
13. Ariflo (SB-207499), an orally active, novel and selective PDE4 inhibitor, had no effect on the steady state pharmacokinetics of digoxin (375mcg od) in healthy volunteers
14. An orally active, novel and selective PDE4 inhibitor, does not potentiate the anti-coagulatory effect of warfarin in healthy male volunteers
15. Safety and efficacy of the new PDE4 inhibitor roflumilast administered to patients with exercise-induced asthma over 4 weeks
16. The safety and tolerability of ariflo (SB 207499), a novel and selective phosphodiesterase 4 inhibitor, in healthy male volunteers
17. Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose
18. Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 Inhibitor, BAY 19-8004
19. The evaluation of a selective phosphodiesterase (PDE) 4 inhibitor, Bay 19-8004, in guinea-pig antigen challenge and ferret emesis models
20. The effect of an oral phosphodiesterase (PDE) 4 inhibitor bay 19-8004 in primate asthma models
21. Efficacy of the selective phosphodiesterase (PDE) 4 Inhibitor, bay 19-8004, in a rat model of neutrophilic lung inflammation
22. Cipamfylline - A promising drug for topical treatment of atopic dermatitis
23. Drug development pipeline: D-4396/D-4418
24. Benzofuran based PDE4 inhibitors
25. Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]-indoles: Novel PDE4 inhibitors
26. Substituted furans as inhibitors of the PDE4 enzyme
27. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils
28. Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells
29. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B
30. The RACK1 signaling scaffold protein selectively interacts with the CAMP-specific phosphodiesterase PDE4D5 isoform
31. Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors
32. Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: A novel class of potent and selective phosphodiesterase Type 4D inhibitors
33. Analysis of a mutation in phosphodiesterase Type 4 that alters both inhibitor activity and nucleotide selectivity
34. Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity
35. Conformational difference between PDE4 apoenzyme and holoenzyme